CURRENTLY ENROLLING CLINICAL TRIALS

Clinical Research

Please contact your provider to learn if you are eligible for any of our enrolling clinical trials.  

Benefits to participants

  • Learn more about your condition
  • Get free study-related eye examinations, when appropriate
  • Help others by assisting researchers to find better and more effective treatments
  • Receive possible financial compensation for your time

 

Age-Related Macular Degeneration

ReNEW – SPIAM-301
Office: Teaneck

A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration

Eyepoint LUCIA EYP-1901-302
Offices: Toms River & Edison

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

4DMT 4D-150-C003
Office: Edison

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1)

Diabetic Retinopathy

CRIMSON – 1436-0007
Office: Teaneck

A multicenter randomized, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy

Geographic Atrophy

Astellas Reveal 3021-MA-3543
Offices: Toms River & Edison

A Non-Interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Questions?
Contact us today! We’re here to help!

Loading ...

©All Rights Reserved. NJRetina 2025